OPFOLDA Drug Patent Profile
✉ Email this page to a colleague
When do Opfolda patents expire, and what generic alternatives are available?
Opfolda is a drug marketed by Amicus Therap Us and is included in one NDA. There are ten patents protecting this drug.
The generic ingredient in OPFOLDA is miglustat. Seven suppliers are listed for this compound. Additional details are available on the miglustat profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Opfolda
A generic version of OPFOLDA was approved as miglustat by ANI PHARMS on April 17th, 2018.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OPFOLDA?
- What are the global sales for OPFOLDA?
- What is Average Wholesale Price for OPFOLDA?
Summary for OPFOLDA
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OPFOLDA |
US Patents and Regulatory Information for OPFOLDA
OPFOLDA is protected by ten US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | 12,419,937 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | 10,961,522 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | 11,753,632 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | 10,857,212 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | 12,414,985 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | 12,246,062 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OPFOLDA
See the table below for patents covering OPFOLDA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 102348 | ⤷ Start Trial | |
| Australia | 2015325028 | ⤷ Start Trial | |
| Australia | 2022203498 | ⤷ Start Trial | |
| Australia | 2025201108 | ⤷ Start Trial | |
| Brazil | 112017005810 | ⤷ Start Trial | |
| Canada | 2961762 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPFOLDA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 4273241 | 122025000021 | Germany | ⤷ Start Trial | PRODUCT NAME: CIPAGLUCOSIDASE ALFA; AUTHORISATION NO/DATE: EU/1/22/1714 20230320 |
| 3201320 | C20240010 | Finland | ⤷ Start Trial | PRODUCT NAME: ALFATSIPAGLUEKOSIDAAS;REG NO/DATE: EU/1/22/1714 24.03.2023 |
| 4273241 | CA 2025 00017 | Denmark | ⤷ Start Trial | PRODUCT NAME: CIPAGLUCOSIDASE ALFA; REG. NO/DATE: EU/1/22/1714 20230324 |
| 3201320 | LUC00336 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: CIPAGLUCOSIDASE ALFA; AUTHORISATION NUMBER AND DATE: EU/1/22/1714 20230324 |
| 4273241 | 2025C/525 | Belgium | ⤷ Start Trial | PRODUCT NAME: CIPAGLUCOSIDASE ALFA; AUTHORISATION NUMBER AND DATE: EU/1/22/1714 20230324 |
| 3201320 | PA2024509 | Lithuania | ⤷ Start Trial | PRODUCT NAME: CIPAGLIUKOZIDAZE ALFA; REGISTRATION NO/DATE: EU/1/22/1714 20230320 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch